Entities / Company
Alector (United States).
company in San Francisco, United States
- Reports this week
- 0
- Active events
- 0
- Connections
- 29
What's happening
Gone quiet
No new reports in 90+ days-
Mizuho upgraded Alector on August 1, 2025, based on the anticipation of positive Phase 3 trial data for latozinemab, Alector's lead asset for FTD, expected in Q4 2025.Some support1 report
-
GSK and Alector announced a strategic collaboration focused on late-stage clinical trials.Some support1 report
-
Dr. Darby was named Director of the Frontotemporal Dementia Clinic at Vanderbilt University Medical Center.Some support1 report1 development inside
-
Ryan Jones transitioned to strategic advisor at Alector, where he was joined by a former CFO, as AI stocks continue to benefit from Trump-era tariffs.Some support1 report
-
Alector is developing latozinemab in collaboration with GSK, and the FDA granted Breakthrough Therapy designation for the drug, which targets FTD-GRN.Some support1 report1 development inside
-
Alector, a biomedical company, underperformed the S&P 500 market gain on August 8, 2025.Some support1 report
-
Alector, a company, is headquartered in South San Francisco, California.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Alector (United States) this week
News at the entities that move Alector (United States) most-
GSK OperationalClement Fourny joins Biodextris as CEO, a company that originated as a GSK development center.Moves Alector (United States)
Connections
The 3 strongest of 29, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
GSK Operational
GSK and Alector maintain a strategic partnership to co-develop neurodegenerative disease treatments, including AL101.
-
Arnon Rosenthal Structural
Arnon Rosenthal serves as the Chief Executive Officer of Alector.
-
Giacomo Salvadore Structural
Alector formally employed Giacomo Salvadore as Chief Medical Officer.
History
Events by the month they beganJune 2026
7 events- Mizuho upgraded Alector on August 1, 2025, based on the anticipation of positive Phase 3 trial data for latozinemab, Alector's lead asset for FTD, expected in Q4 2025.
- GSK and Alector announced a strategic collaboration focused on late-stage clinical trials.
- Dr. Darby was named Director of the Frontotemporal Dementia Clinic at Vanderbilt University Medical Center.
- Ryan Jones transitioned to strategic advisor at Alector, where he was joined by a former CFO, as AI stocks continue to benefit from Trump-era tariffs.
- Alector is developing latozinemab in collaboration with GSK, and the FDA granted Breakthrough Therapy designation for the drug, which targets FTD-GRN.
- Alector, a biomedical company, underperformed the S&P 500 market gain on August 8, 2025.
- Alector, a company, is headquartered in South San Francisco, California.